Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive
Fecha de publicación
2015Título de revista
Journal Of Clinical Oncology
Tipo de contenido
Publicación de congreso